Relief Therapeutics Holding AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Relief Therapeutics Holding AG
The EU vaunts its vaccine donations and starts building resilience against future health threats, and the UK MHRA says Moderna can be used as a booster dose. Aviptadil has received scientific advice from the MHRA for its potential use as a treatment for COVID-19 patients.
Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised
ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
- Large Molecule
- Other Names / Subsidiaries
- APR Applied Pharma Research SA
- THERAMetrics Holding AG